Prothena_RGB_fullcolor.jpg
Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update
May 11, 2021 16:05 ET | Prothena Corporation plc
Net cash used in operating and investing activities was $33.7 million in the first quarter; quarter-end cash and restricted cash position of $345.7 million provides funding to advance the R&D...
Prothena_RGB_fullcolor.jpg
Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease
May 10, 2021 16:05 ET | Prothena Corporation plc
DUBLIN, Ireland, May 10, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein...
Prothena_RGB_fullcolor.jpg
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 07, 2021 16:05 ET | Prothena Corporation plc
DUBLIN, Ireland, May 07, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein...
Prothena_RGB_fullcolor.jpg
Prothena to Report First Quarter 2021 Financial Results on May 11th
May 04, 2021 16:05 ET | Prothena Corporation plc
DUBLIN, Ireland, May 04, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational...
Prothena_RGB_fullcolor.jpg
Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
April 18, 2021 15:05 ET | Prothena Corporation plc
Slowing of neuropathy progression for all 7 evaluable patients, evidenced by a +1.29 point mean change in NIS, was more favorable than expected progression of +9.2 pointsImprovement in neuropathy for...
Prothena_RGB_fullcolor.jpg
Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021
April 15, 2021 16:05 ET | Prothena Corporation plc
DUBLIN, Ireland, April 15, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational...
Prothena_RGB_fullcolor.jpg
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 07, 2021 16:05 ET | Prothena Corporation plc
DUBLIN, Ireland, April 07, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational...
Prothena_RGB_fullcolor.jpg
Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer
April 05, 2021 16:05 ET | Prothena Corporation plc
DUBLIN, Ireland, April 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational...
Prothena_RGB_fullcolor.jpg
Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares
March 24, 2021 08:00 ET | Prothena Corporation plc
DUBLIN, Ireland, March 24, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational...
Prothena_RGB_fullcolor.jpg
Prothena Announces Proposed Offering of Ordinary Shares
March 23, 2021 16:29 ET | Prothena Corporation plc
DUBLIN, Ireland, March 23, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational...